Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed London Stock Exchange - 04/17 11:35:23 am
1559 GBp   -0.29%
12h ago Pfizer considers $100 billion bid for AstraZeneca
2d ago GLAXOSMITHKLINE : Assigned Patent
2d ago GLAXOSMITHKLINE : GSK and Genmab receive FDA approval for Arzerra (ofatumum..
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

GlaxoSmithKline plc : Glaxo's Malaria Drug Gets US Breakthrough Therapy Designation

12/20/2013 | 11:10am US/Eastern
Recommend:
0

By Rory Gallivan

LONDON--GlaxoSmithKline PLC (GSK.LN) Friday said the U.S. Food and Drug Administration has given its malaria treatment tafenoquine a designation that aims to speed up the approval process for drugs used to treat life-threatening diseases.

The FDA has granted tafenoquine Breakthrough Therapy designation, Glaxo said, adding that tafenoquine is not yet approved or licensed for use anywhere in the world.

-Shares at 1546 GMT, down a penny, or at 1,572 pence, valuing the company at GBP76.37 billion ($125.1 million).

Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Recommend :
0
React to this article
Latest news on GLAXOSMITHKLINE PLC
12h ago Pfizer considers $100 billion bid for AstraZeneca
2d ago GLAXOSMITHKLINE : Assigned Patent
2d ago GLAXOSMITHKLINE : GSK and Genmab receive FDA approval for Arzerra (ofatumumab) a..
3d ago GLAXOSMITHKLINE : GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) ..
3d ago China's new breed of whistleblowers takes on big business
3d ago GLAXOSMITHKLINE : GSK announces approval in Canada for Incruse™ Ellipta&tr..
3d agoDJGLAXOSMITHKLINE : GSK Says Incruse Gets Approval in Canada for Treatment of Lung..
3d ago GLAXOSMITHKLINE : GSK announces approval in Canada for Incruse Ellipta (umeclidi..
3d ago GLAXOSMITHKLINE : GSK receives approval in Canada for Incruse
3d ago GLAXOSMITHKLINE : Glaxo COPD Treatment Incruse Ellipta Cleared In Canada
Advertisement
Chart
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Income Statement Evolution
GlaxoSmithKline plc : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF